Drs. George Martin and Ted Rosen talk candidly about why JAK inhibitors are important in the treatment of atopic dermatitis (AD), when dermatologists should consider using them, and how to safely mitigate risks and side effects while effectively treating AD patients with these powerful, “revolutionary” medications.

0:50 – The role of JAKs in AD

4:50 – JAK nuances

9:13 – The ORAL study and expanded black box warning

15:07 – Newer JAKS and Black Box inheritance

17:00 – The new molecules

18:00 – How to present biologics vs JAKs (age + delivery)

21:10 – Women of childbearing years

27:00 – Legacy black box on mace events, PEs, and DVTs – who’s at risk?

30:44 – Cancer and risk

32:10 – Patients at risk for serious infections

35:27 – JAKs and vaccinations

38:47 – Dosing adjustments

46:20 – Final thoughts on biologics and JAKs

Tips for Avoiding Common Sources of Pediatric Allergen Contact Dermatitis

The Dermatology Digest Podcast ExclusivesBy The Dermatology DigestApr 28, 2022